ATE497784T1 - Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen - Google Patents

Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen

Info

Publication number
ATE497784T1
ATE497784T1 AT04808124T AT04808124T ATE497784T1 AT E497784 T1 ATE497784 T1 AT E497784T1 AT 04808124 T AT04808124 T AT 04808124T AT 04808124 T AT04808124 T AT 04808124T AT E497784 T1 ATE497784 T1 AT E497784T1
Authority
AT
Austria
Prior art keywords
gene
heart diseases
diseases
drug
heart
Prior art date
Application number
AT04808124T
Other languages
English (en)
Inventor
Kenichiro Kosai
Hiroaki Ushikoshi
Original Assignee
Nagoya Ind Science Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagoya Ind Science Res Inst filed Critical Nagoya Ind Science Res Inst
Application granted granted Critical
Publication of ATE497784T1 publication Critical patent/ATE497784T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
AT04808124T 2003-12-26 2004-12-24 Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen ATE497784T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003432279 2003-12-26
PCT/JP2004/019774 WO2005063302A1 (ja) 2003-12-26 2004-12-24 Ｃｄ９遺伝子からなる心疾患を予防又は治療する医薬

Publications (1)

Publication Number Publication Date
ATE497784T1 true ATE497784T1 (de) 2011-02-15

Family

ID=34736470

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04808124T ATE497784T1 (de) 2003-12-26 2004-12-24 Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen

Country Status (6)

Country Link
US (1) US7803780B2 (de)
EP (1) EP1716869B1 (de)
JP (1) JP4736088B2 (de)
AT (1) ATE497784T1 (de)
DE (1) DE602004031381D1 (de)
WO (1) WO2005063302A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013200106B2 (en) * 2006-04-21 2015-10-01 Intervet International Bv Pestivirus Species
KR20200122601A (ko) * 2019-04-18 2020-10-28 황정후 Cd9을 이용한 퇴행성 신경질환의 예방 또는 치료용 조성물과 퇴행성 신경질환 치료제 스크리닝 방법
US11905249B2 (en) 2021-01-25 2024-02-20 Jackson State University Covalent inhibitors of equine encephalitis virus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001523103A (ja) * 1997-04-28 2001-11-20 ローヌ−プーラン・ロレ・エス・アー 腫瘍治療用血管形成アンタゴニストのアデノウイルスによる腫瘍内送達
US7060433B1 (en) * 1999-11-12 2006-06-13 Rigel Pharmaceuticals, Inc. Methods and compositions for screening using diphtheria toxin constructs

Also Published As

Publication number Publication date
JP4736088B2 (ja) 2011-07-27
EP1716869A4 (de) 2007-05-23
WO2005063302A1 (ja) 2005-07-14
EP1716869B1 (de) 2011-02-09
EP1716869A1 (de) 2006-11-02
DE602004031381D1 (de) 2011-03-24
US20070161584A1 (en) 2007-07-12
US7803780B2 (en) 2010-09-28
JPWO2005063302A1 (ja) 2007-07-19

Similar Documents

Publication Publication Date Title
PL378030A1 (pl) Czynniki które regulują, hamują lub modulują działanie i/lub wyrażanie czynnika wzrostowego tkanki łącznej (CTGF), jako wyjątkowe środki do obniżania ciśnienia śródgałkowego i leczenia retinopatii jaskrowej/neuropatii nerwu wzrokowego
CA2278842A1 (en) Use of peroxygen compounds in the control of hairy wart disease
CY1110400T1 (el) Η χρηση της ρανολαζινης για την παρασκευη ενος φαρμακου για την θεραπεια των αρρυθμιων
DE69718612D1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
EP1461352A4 (de) Antisense-modulation der expression von bindegewebewachstumsfaktor
NO20044940L (no) Rekombinant poxvirus som uttrykker homologe gener innsatt i det poxvirale genomet
DE60019473D1 (de) (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
DE60028863D1 (de) Elektrochirurgisches Handstück zur Behandlung von Gewebe
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE491715T1 (de) Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
DE60009146D1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten
EP1343532A4 (de) Durch lentiviralen vektor vermittelter gentransfer und anwendungszwecke
ATE497784T1 (de) Arznei zur prävention und behandlung von herzerkrankungen mit cd9-gen
DE60231649D1 (de) Mittel zur behandlung von augentrockenheit und damit zusammenhängenden erkrankungen
DE60111620D1 (de) Aktiviertes protein c zur behandlung von pankreatitis
DE60231246D1 (de) Superoxiddismutas-mimetika zur behandlung von augenerkrankungen
DE602005020178D1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
AP9901474A0 (en) Pharmaceutical composition for treating viral diseases.
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
ATE285764T1 (de) Rivastigmine zur behandlung von augenerkrankungen
MXPA05004121A (es) Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
EP1062948A4 (de) Arzneimittel für diastolische herzerkrankungen
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties